Skip to main content
Fig. 4 | BMC Gastroenterology

Fig. 4

From: Hyperprogressive disease during atezolizumab plus bevacizumab treatment in patients with advanced hepatocellular carcinoma from Japanese real-world practice

Fig. 4

Overall survival of HPD and PD without HPD and non-PD. HPD was defined as a more than twofold (A) or fourfold (B) increases of TGR or TGKR in patients determined to have PD by RECIST v1.1 at the first response. Landmark survival analyses at 12 weeks to compare OS between PD without HPD, and PD with HPD groups were also analyzed as a more than twofold (C) or fourfold (D) increases of TGR or TGKR in patients determined to have PD by RECIST v1.1 at the first response

Back to article page

BMC Gastroenterology

ISSN: 1471-230X

Contact us